Skip to main content
x

Preparing Patients for Cancer Treatment Decisions


[Editor’s Note: Underserved patient groups like agricultural workers are at higher risk of certain cancers. In this post, the University of Florida College of Medicine invites health care providers to take trainings on cancer care and clinical trials that are available. This post is sponsored by University of Florida College of Medicine.]

Primary care providers, including physicians, physician associates/physician assistants, and nurse practitioners, who have referred their patients to specialists for cancer treatment in the past year, are invited to participate in a free, online, self-guided training as part of a research study. The course is designed to enhance the important work you do to prepare your patients for cancer treatment discussions, including raising your awareness of clinical trials as a treatment option. You will learn from a radiation oncologist, Raymond Mailhot, MD, MPH; Primary Care Provider, Ana Natale-Pereira, MD, MPH; and a Clinical Trials Expert, Margo Michaels, MPH. CME or CE credit is available for your participation in the course.

Compensation is available for completing the research surveys.

Learning Objectives

After completing this accredited activity, the participant should be better able to:

  • Strengthen your knowledge around disparities in cancer care and in clinical trials
  • Understand the importance of your role in preparing patients for referral
  • Foster your patients’ engagement in cancer care
  • Consider changes to your referral process



You will be asked to complete brief surveys before and after the program as part of the research study led by Carma Bylund, PhD at the University of Florida in collaboration with Elisa Weiss, PhD at The Leukemia & Lymphoma Society (University of Florida, ET00021321). You are eligible to participate in this study if you meet all of the following requirements:

  • You are a physician, physician associate/physician assistant, or nurse practitioner currently providing primary care in an outpatient setting
  • You have made patient referrals to specialists for cancer treatment in the last year
  • You are an English speaker and reside in the US or its territories
     

To compensate you for your time and participation in the surveys, eligible participants who complete the pre- and post-training surveys (approximately 15 minutes total) will be sent a $150 gift card. An additional $20 gift card will be sent upon completion of the three-month post survey, and an additional $25 gift card will be sent upon completion of the six-month post survey (approximately 10 minutes total). 


CME for Physicians and Physician Associates/Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and The Leukemia & Lymphoma Society. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online training.
 

CE for Nurses

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

There are no fees for participating in or receiving credit for this CE activity. To be eligible to earn CE credit, you must complete the entire course, including the post-test and evaluation. Once you have completed the course, a certificate of completion will be emailed to you.
 


How to Participate

To participate, fill out the interest form here, or contact study coordinator Alyssa Crowe at alyssacrowe@ufl.edu

Support for this program is provided by The Leukemia & Lymphoma Society (PHP9007-22 & HSR9019-23), Amgen Inc., Bristol Myers Squibb, AbbVie Inc., and AstraZeneca Pharmaceuticals LP.